Paradoxes of evidence-based medicine in lower-grade glioma: To treat the tumor or the patient?

Neurology
H Duffau

Abstract

Brain lower-grade gliomas (LGG) usually occur in young adults who enjoy an active life. This tumor has a high risk of malignant transformation resulting in neurologic deterioration and finally death. Early and multistage therapeutic management can increase survival over 10 years. Preservation of functional neural networks and quality of life is crucial. In the era of evidence-based medicine, the issues discussed are those associated with the design, analysis, and clinical application of randomized controlled trials (RCTs) for LGG. RCTs should take account of the following: considerable variability in the natural course of LGG; limited prognostic value of molecular biology at the individual level; large variability of brain organization across patients; technical and conceptual progress of therapies over years; combination or repetition of iterative treatments, taken as a whole and not only in isolation; and long-term consequences on oncologic and functional outcomes. As it is difficult to translate the results of an RCT into benefits for a unique patient with LGG, personalized decisions must be made by considering the tumor behavior, individual pattern of neuroplasticity, and patient needs, and not by administrating a standardi...Continue Reading

References

Jan 13, 1996·BMJ : British Medical Journal·D L SackettW S Richardson
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 20, 2005·Lancet·M J van den BentUNKNOWN EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin S SmithMitchel S Berger
Jul 16, 2008·Archives of Neurology·Howard Colman, Ken Aldape
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karin GehringNeil K Aaronson
May 11, 2011·Brain Pathology·Valérie RigauUNKNOWN Association des Neuro-Oncologues d’Expression Française (ANOCEF)
Apr 21, 2012·Cancer Cell·Paul WorkmanBissan Al-Lazikani
Apr 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip C De Witt HamerMitchel S Berger
Aug 15, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johan W de Fijter, Jan Nico Bouwes Bavinck
Sep 21, 2013·Cortex; a Journal Devoted to the Study of the Nervous System and Behavior·Hugues Duffau
Jan 1, 2014·Brain : a Journal of Neurology·Johan PalludGilles Huberfeld
Mar 13, 2014·PloS One·Xiaowei GuanJill S Barnholtz-Sloan
Aug 7, 2014·Neuro-oncology·Johan Pallud, Hugues Duffau
Sep 30, 2014·Journal of Neuro-oncology·Dominik CordierHugues Duffau
Jun 11, 2015·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkJianan Zhang
Jun 20, 2015·Acta Neuropathologica·David E ReussAndreas von Deimling
Feb 26, 2016·Brain : a Journal of Neurology·Guillaume HerbetHugues Duffau
Feb 28, 2016·Cortex; a Journal Devoted to the Study of the Nervous System and Behavior·Hugues Duffau
Mar 22, 2016·CNS Oncology·Victor A Levin
Apr 7, 2016·The New England Journal of Medicine·Jan C BucknerWalter J Curran
Jul 16, 2016·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Christopher H ChapmanYue Cao
May 6, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S JakolaO Solheim
May 10, 2017·The Lancet Oncology·Michael WellerUNKNOWN European Association for Neuro-Oncology (EANO) Task Force on Gliomas
Jun 9, 2017·The Lancet Oncology·Andrea PaceUNKNOWN European Association of Neuro-Oncology palliative care task force
Aug 2, 2017·The Lancet Oncology·UNKNOWN European Low-Grade Glioma Network (see appendix for full list of contributors). Electronic address: elggn2006@gmail.com
Sep 18, 2017·Neurosurgery Clinics of North America·Ganesh Rao

❮ Previous
Next ❯

Citations

Dec 4, 2019·Oncology Letters·Jing XueWei Zhang
Nov 17, 2020·Frontiers in Oncology·Tiphaine ObaraLuc Taillandier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Handbook of Clinical Neurology
M S BergerWolfgang Wick
Journal of Neurosurgery
N SanaiM S Berger
The Korean Journal of Hepatology
Dong Hun Park, Soon Koo Baik
Seminars in Radiation Oncology
Mary Frances McAleer, Paul D Brown
© 2022 Meta ULC. All rights reserved